Outlook Therapeutics, Inc.
OTLK
$1.37
-$0.02-1.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 113.28% | 153.29% | 0.90% | -- | -54.07% |
| Gross Profit | -113.28% | -153.29% | -0.90% | -- | 54.07% |
| SG&A Expenses | 106.20% | 37.78% | 18.76% | -13.70% | -0.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 109.31% | 83.62% | 7.83% | 176.99% | -34.20% |
| Operating Income | -109.31% | -83.62% | -7.83% | -176.99% | 34.20% |
| Income Before Tax | 255.46% | 143.81% | 314.80% | -1,618.20% | 40.10% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | 255.46% | 143.81% | 314.80% | -1,617.52% | 40.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 255.46% | 143.81% | 314.80% | -1,617.52% | 40.10% |
| EBIT | -109.31% | -83.62% | -7.83% | -176.99% | 34.20% |
| EBITDA | -109.60% | -83.56% | -7.74% | -177.02% | 34.33% |
| EPS Basic | 183.48% | 124.01% | 218.78% | -1,444.63% | 47.66% |
| Normalized Basic EPS | 198.49% | 127.97% | 214.69% | -1,330.61% | 50.79% |
| EPS Diluted | 183.38% | 124.01% | 45.03% | -1,444.63% | 47.60% |
| Normalized Diluted EPS | 198.49% | 127.97% | 204.56% | -1,330.61% | 50.79% |
| Average Basic Shares Outstanding | 86.23% | 82.47% | 80.84% | 11.20% | 14.44% |
| Average Diluted Shares Outstanding | 86.23% | 82.47% | 98.35% | 11.20% | 14.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |